News
-
-
COMMUNIQUÉ DE PRESSE
Secarna establishes Scientific Advisory Board with leading oncology experts Prof. Dr. Eggermont and Prof. Dr. Zippelius
Secarna Pharmaceuticals GmbH & Co. KG establishes an oncology Scientific Advisory Board with leading experts Prof. Dr. Eggermont and Prof. Dr. Zippelius to guide the development of SECN-15 and the oncology pipeline -
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics showcasing strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs
Secarna Pharmaceuticals publishes new data in Nucleic Acid Therapeutics highlighting strategies to detect and prevent immunostimulatory potential of LNA-modified ASOs -
-
-
COMMUNIQUÉ DE PRESSE
Secarna Pharmaceuticals and Orbit Discovery enter collaboration to discover and develop peptide-conjugated targeted antisense oligonucleotide therapeutics
Secarna Pharmaceuticals and Orbit Discovery collaborate to develop peptide-conjugated targeted antisense oligonucleotide therapeutics, expanding treatment options for various diseases -
-
